Last reviewed · How we verify
Salmon Calcitonin
Salmon calcitonin is a peptide hormone that binds to calcitonin receptors on osteoclasts to inhibit bone resorption and lower serum calcium levels.
Salmon calcitonin is a peptide hormone that binds to calcitonin receptors on osteoclasts to inhibit bone resorption and lower serum calcium levels. Used for Paget's disease of bone, Hypercalcemia of malignancy, Osteoporosis in postmenopausal women.
At a glance
| Generic name | Salmon Calcitonin |
|---|---|
| Also known as | Miacalcic nasal spray (Novartis Pharmaceutical) |
| Sponsor | Eli Lilly and Company |
| Drug class | Calcitonin receptor agonist |
| Target | Calcitonin receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Bone metabolism |
| Phase | FDA-approved |
Mechanism of action
Calcitonin is a 32-amino acid peptide that acts as a potent inhibitor of osteoclast-mediated bone resorption. It binds to calcitonin receptors on the surface of osteoclasts, causing them to retract from the bone surface and reducing their resorptive activity. This leads to decreased serum calcium and phosphate levels and is used therapeutically in conditions characterized by elevated bone turnover or hypercalcemia.
Approved indications
- Paget's disease of bone
- Hypercalcemia of malignancy
- Osteoporosis in postmenopausal women
- Acute bone loss following immobilization
Common side effects
- Nausea
- Flushing
- Injection site reactions
- Headache
- Diarrhea
Key clinical trials
- A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults (PHASE1)
- Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients (PHASE4)
- Paravertebral Calcitonin in Thoracotomy (NA)
- Evaluation of Pulpal and Salivary Neuropeptides in Dental Pain
- Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens (PHASE4)
- Procalcitonin and Threatened Premature Delivery (NA)
- Chinese Real-world Study of Treatment of Vestibular Migraine
- Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Salmon Calcitonin CI brief — competitive landscape report
- Salmon Calcitonin updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI